The Alzheimer’s Association has committed funding to two major venture investments aimed at accelerating the discovery and development of new treatments for Alzheimer’s disease and other dementias. The Association has invested about $10.85 million in EQT Life Sciences’ LSP Dementia Fund and $10 million in the Dementia Discovery Fund 2. Both funds support companies developing new therapies for brain diseases.

Through these investments, the Alzheimer’s Association participates as a limited partner in each venture fund. This means the Association helps provide funding but does not choose which companies receive the investments. Those decisions are made by each fund’s independent investment committee. These committees include experts who review the scientific promise and business potential of each opportunity. This structure allows the Association’s funding to support promising research while maintaining the independent oversight that is standard in venture investing.

This approach reflects the Association’s growing role in advancing scientific progress across the full research pathway. The organization supports work from early discovery and seed-stage research to later stages of clinical development. By investing in specialized venture funds led by experts in dementia science and biotechnology, the Association helps ensure that promising treatment ideas have the resources they need to move toward clinical testing and, ultimately, patient access.

These venture investments build on the Association’s strong global research portfolio. This includes Part the Cloud, a program that has supported dozens of early clinical trials and helped generate more than $1 billion in follow-on funding from government and industry partners.

Learn more about our commitment to transparency. View the Association's governance policies, financial reports and partnership information.